A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was 'in patients with non-small-cell lung cancer who have undergone complete resection, does the presence of microvascular invasion (MVI) significantly impact long-term survival or prognosis?' Altogether, more than 250 papers were found using the reported search, of which 12 represented the best evidence to answer the clinical question. Outcome parameters that were used in the assessment include 5-year overall survival, event-free or recurrence-free survival (RFS) and incidence of metastatic relapse. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses were tabulated. The majority of the data collected were retrospective. Meta-analysis of data of over 16 000 patients showed that when considering RFS, MVI positivity was associated with a significantly reduced period of RFS; pooled hazard ratio estimates by univariate and multivariate analyses were 3.28 (95% CI 2.14-5.05; P < 0.0001) and 3.98 (95% CI 2.24-7.06; P < 0.0001), respectively. Eight of the studies showed a significantly worse 5-year survival in the presence of MVI, whereas a further study found a reduced median survival with MVI. One study showed no difference, but concurred with five other studies that MVI was associated with a significantly shorter event-free or RFS. Multivariate analyses have furthermore demonstrated that MVI positivity correlates with larger tumour size, an increased risk of distant metastases, visceral pleural involvement, lymphovascular invasion, higher tumour grade and nodal status. We conclude that the presence of microvascular invasion in resected early-stage non-small-cell lung cancer is a negative prognostic factor.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] . 
THREE-PART QUESTION
In
CLINICAL SCENARIO
You are working in the tertiary thoracic surgery centre and are reviewing the histology specimens from patients who have undergone complete R0 resection for non-small-cell lung cancer. You note that some specimens have been flagged as demonstrating the presence of microvascular invasion, whereas others have not. You are unsure as to the clinical significance of this finding and resolve to search the literature yourself. 
SEARCH STRATEGY
A
SEARCH OUTCOME
The search yielded 259 papers. Relevant papers were identified and their references screened; papers were excluded unless they specifically mentioned 'microvascular' or 'microscopic vascular invasion'. Of these, 12 papers were considered to offer the best evidence to answer our clinical question. These are presented in Table 1 . Overall and disease-free 5-year survival rates between those who displayed MVI positivity and those who did not were 42.8 vs 50.9% (P = 0.013) and 78.8% (same rate in both cohorts; P = 0.75), respectively. The overall incidence rate of vascular invasion in this group was 23.4%, which showed statistically significant correlation with the grade of tumour (P = 0.019), visceral pleural involvement (P = 0.033), lymphovascular space invasion (P < 0.001) and nodal status (P = 0.03). Bodendorf et al. [3] retrospectively analysed 112 patients who had undergone curative resection of NSCLC. MVI was found in 45.5% of resected tumours (V1 group). The 5-year survival rate was found to be 56.0% in the cohort without MVI and 37.2% in the V1 group (P = 0.0249). This group additionally reasoned that adjuvant radiation in node-positive cases would have little influence in preventing distant metastasis even in early-stage tumours.
Gabor et al. [4] retrospectively analysed 72 patients who had undergone R0 resection for T1-T3N0M0 NSCLC, 11 of whom exhibited MVI on histology. RFS was 16 months in the MVI cohort compared with 19 months in the group as a whole (statistically insignificant). Five-year overall survival (OS) was found to be significantly reduced in the MVI cohort: 23.5 vs 74.5% in those without MVI (P < 0.01).
Hamanaka et al. [5] carried out a clinicopathological analysis on 467 patients with pathological-stage I NSCLC. Thirty-seven of 335 patients exhibited blood vessel invasion. The recurrence-free survival rate in those with and without blood vessel invasion was 62.2 vs 96.2%, respectively (P < 0.0001).
Hishida et al. [6] carried out a retrospective analysis on a similar group of patients; 358 out of 1039 patients exhibited MVI. Five-year OS was significantly reduced in the MVI-positive cohort compared with the microlymphatic permeation cohort (P = 0.002).
Kessler et al. [7] studied 593 patients who had undergone curative resection of NSCLC between November 1983 and December 1988. In this cohort, 284 patients exhibited MVI. The overall median survival was 3.2 years. The median survival in the MVI-negative and the MVI-positive cohorts was 1816 ± 176 vs 713 ± 56 days, respectively (P < 0.0001). This series found that MVI positivity was a strong independent prognostic risk factor, more so than T stage but less so than the N stage.
Neri et al. [8] retrospectively analysed 2657 consecutive patients with pathological T1-4N0-2M0 NSCLC who had undergone complete resection. The overall 5-year survival rate of those with and without MVI was 57.2 vs 87.3%, respectively (P < 0.001). The 5-year recurrence-free survival rate of those with and without MVI was 52.6 and 87.5%, respectively (P < 0.001). Of the patients who developed recurrence, distant metastases were found more frequently in those with MVI (P < 0.001). Furthermore, MVI was the most powerful predictor of recurrence, with its hazard ratio of 2.78 being greater than that of pathological nodal status ( pN; hazard ratio 2.58).
Interestingly, Rigau et al. [9] showed that MVI positivity had no significant prognostic weight in terms of reducing 5-year OS (P = 0.10), but it did significantly reduce event-free survival (P = 0.025).
Ruffini et al. [10] analysed a cohort of 746 patients with T1-T2N0M0 NSCLC who had undergone R0 resection; 257 patients exhibited MVI. MVI positivity was significantly associated with reduced 5-year OS rates (P = 0.001) and in the adenocarcinoma subgroup (P = 0.002).
Shimada et al. [11] retrospectively analysed 532 patients who underwent complete resection of stage IA NSCLC. The overall 5-year survival and 5-year recurrence-free survival between those with and without MVI was 72.1 vs 86.2% (P < 0.002) and 71.3 vs 88.1%, respectively (P < 0.001). Shoji et al. [12] identified 217 patients with resected stage IA NSCLC. Within this group, 8.8% (n = 19) exhibited MVI, which was found to be an independent negative prognostic risk factor (P = 0.0006). In terms of disease-free survival, the relative risk for patients with MVI was 4.599 times higher than those without MVI (95% CI 1.913-11.056). The authors identified the need for prospective data in order to evaluate the survival benefit of adjuvant therapy in MVI-positive early-stage tumours.
A recent meta-analysis [13] of 16 535 included patients deemed, through univariate and multivariate analyses, that pooled hazard ratio estimates were significant (P < 0.0001) in showing that OS and RFS were reduced with MVI positivity. Wang's group used five of the studies that are included in this review. This analysis was, however, limited; the studies showed evidence of significant heterogeneity in terms of patient characteristics, treatment definition and duration of follow-up, and included vascular invasion as opposed to true MVI. In addition to these points, subgroup analysis indicated that disparity between methods of assessing vascular invasion contributed largely to heterogeneity. Finally, those studies that reported on adjuvant chemotherapy failed to appropriately detail the type of therapy received, i.e. whether therapies targeted the epidermal growth factor receptor, a factor which can be instrumental to patient outcome in NSCLC.
CLINICAL BOTTOM LINE
Microscopic invasion of blood vessels in NSCLC has consistently been shown to be independently associated with an unfavourable prognosis. The incorporation of MVI status into the next revision of the TNM staging system may aid clinicians in identifying higherrisk patients, thus assisting the decision-making process regarding the need for adjuvant therapy.
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